13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $113M | -$352M | 99.3% | -226.0% | -$309M | — | $88M |
| 2024 | $15M | -$414M | 100.0% | -2334.2% | -$398M | — | $143M |
| 2023 | $622000 | -$584M | 100.0% | -58239.5% | -$397M | — | $265M |
| 2022 | $240000 | -$417M | 100.0% | -146374.2% | -$416M | — | $105M |
| 2021 | — | -$350M | — | — | -$308M | — | $181M |
| 2020 | — | -$222M | — | — | -$173M | — | $35M |
| 2019 | — | -$158M | — | — | -$156M | — | $76M |
| 2018 | — | -$96M | — | — | -$76M | — | $17M |
| 2017 | — | -$96M | — | — | -$84M | — | $24M |
| 2016 | — | -$121M | — | — | -$45M | — | $8M |
| 2015 | — | -$237M | — | — | — | — | $176M |
| 2014 | — | -$6M | — | — | — | — | $59M |
| 2013 | — | -$2M | — | — | — | — | $350000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $44M | -$633M | 99.5% | -157.9% | -$77M | — | $205M |
| Dec '25 | $38M | -$62M | 99.0% | -169.0% | -$71M | — | $88M |
| Sep '25 | $32M | -$67M | 99.4% | -173.5% | -$70M | — | $60M |
| Jun '25 | $26M | -$93M | 99.5% | -269.8% | -$81M | — | $138M |
| Mar '25 | $17M | -$130M | 99.6% | -390.1% | -$87M | — | $61M |
| Dec '24 | $8M | -$59M | 100.0% | -919.0% | -$87M | — | $143M |
| Sep '24 | $6M | -$86M | 100.0% | -1314.3% | -$102M | — | $112M |
| Jun '24 | $1M | -$135M | 100.0% | -9487.4% | -$101M | — | $130M |
| Mar '24 | $40000 | -$134M | 100.0% | -237990.0% | -$108M | — | $133M |
| Dec '23 | $139000 | -$233M | 100.0% | -61430.9% | -$123M | — | $265M |
| Sep '23 | $82000 | -$96M | 100.0% | -97726.8% | -$93M | — | $178M |
| Jun '23 | $41000 | -$138M | 100.0% | -207670.7% | -$88M | — | $44M |
| Mar '23 | — | -$116M | — | — | -$93M | — | $88M |
| Dec '22 | — | -$108M | — | — | -$110M | — | $105M |
| Sep '22 | — | -$111M | — | — | -$97M | — | $104M |
| Jun '22 | — | -$95M | — | — | -$107M | — | $62M |
| Mar '22 | — | -$103M | — | — | -$102M | — | $36M |
| Dec '21 | — | -$91M | — | — | -$82M | — | $181M |
| Sep '21 | — | -$88M | — | — | -$81M | — | $65M |
| Jun '21 | — | -$88M | — | — | -$78M | — | $84M |
How the market has priced IBRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Immunitybio, Inc.'s revenue has grown 678.6% per year. These are computed facts, not advice.
As of FY2025, Immunitybio, Inc. reported — of total debt against $88M of cash; operating income covered interest expense -4.2×.
In FY2025, gross margin was 99.3%, operating margin -226.0%, and net margin -310.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.